Circadian rhythms are endogenous biological clocks that govern fundamental physiological and behavioral functions. Consequently, perturbations of these rhythms have been associated with pathogenic conditions, such as depression, diabetes, and cancer. CCAAT/enhancer-binding proteins (C/EBPs) are a family of transcription factors that regulate cell growth and differentiation in various tissues and have also been implicated in many cancer types. Using expression profiling studies, we found that the levels of 2 core components of the circadian network, Per2 and Rev-Erba, are significantly altered by C/EBPs. Further studies showed that levels of Per2 were reduced in lymphoma and acute myeloid leukemia patient samples, as well as in lymphoma cell lines. Overexpression of Per2 in hematopoietic cancer cell lines resulted in growth inhibition, cell cycle arrest, apoptosis and loss of clonogenic ability. These results support the emerging role of circadian genes in tumor suppression.
The differentiation of hematopoietic precursors into the various types of blood cell lineages is tightly regulated. Increasing evidence suggest that a small group of lineagespecific transcription factors have a key role in this process. 1 One family of transcription factors, important to the regulation of cell growth and differentiation in many cell types, including haematopoietic cells, are the CCAAT/enhancer-binding proteins (C/EBPs). 2 Within the hematopoietic system, members of the C/EBP family (a, b, g, d, e, z) are expressed during myeloid development. C/EBPa, the founding member of the family is considered a "master regulator" of steady-state granulopoiesis. It is detected in early myeloid precursors and is upregulated as these cells commit to granulocytic differentiation. C/EPBe is upregulated during differentiation of myeloid cells and is essential for terminal neutrophil differentiation. Disruption of the C/EBPA gene in mice results in loss of production of neutrophils and eosinophils. Mice that lack C/EBPe produce abnormal neutrophils and eosinophils. No apparent defects in granulopoiesis are apparent in C/EBPb and C/EBPd deficient mice; however, C/EBPb is required for granulopoiesis in response to some external singles.
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by the accumulation of immature myeloid cells in the bone marrow and blood as a result of deregulation of normal proliferation, differentiation, and apoptosis. AML is the most frequently diagnosed type of leukemia in adults occurring in approximately one third of new patients. Multiple genetic abnormalities have been implicated in the pathogenesis of AML including chromosomal deletions, amplifications, and chromosomal translocations, as well as small mutations in lineage-specific transcription factors. 3 Among genetic alterations associated with AML and acute lymphoblastic leukemia (ALL), aberrant expression of a transcription factor or the production of an abnormal hybrid transcription factor, are the most common mechanisms described. The importance of C/EBPs to normal cellular proliferation and differentiation predicts that their signaling pathways would be disrupted during malignant transformation. Many studies have confirmed this hypothesis, showing aberrant expression/function of C/EBPs in leukemias and other cancers. Studies from our group and other laboratories showed that the expression or function of C/EBPa is inactivated in specific types of leukemia such as AML and chronic myelocytic leukemia (CML), by diverse molecular mechanisms. 4, 5 On the other hand, overexpression of C/EBPa in leukemic cells restores their differentiation potential. Indeed, C/EBPa is well established not only as a key regulator of normal neutrophil, granulocyte and eosinophil development but also as a potent inhibitor of cell proliferation. Although to a lesser extent, the other C/EBP proteins have also been implicated in hematopoietic neoplasms.
The most important role of C/EBPs is their function as transcriptional regulators in which they control the expression of large sets of genes. To better understand the full spectrum of gene expression under the control of C/EBP proteins, we performed transcriptional profiling analysis with NIH 3T3 cells ectopically expressing C/EBPa, C/EBPb, C/ EBPd, or C/EBPe. 6 Remarkably, functional annotation analysis of the data pointed to a previously unreported relationship between the C/EBP transcription factors and the circadian clock. We identified 2 core circadian genes, Per2 (Period 2) and Rev-Erba, as well as a circadian output gene, Dbp (albumin site d-binding protein), as novel C/EBP targets (Table 1) . Per2 was upregulated, Rev-Erba was downregulated, and Dbp was upregulated by C/EBPb and downregulated by C/EBPa and C/EBPe.
The Circadian Clock
The circadian apparatus is composed of a central pacemaker situated in the suprachiasmatic nucleus (SCN) and local clocks located in peripheral organs. 7 The circadian clockwork in both the central pacemaker and the peripheral organs is regulated by finely tuned transcription-translation feedback loops and posttranslational modifications, which are maintained by a core set of clock genes. The positive feedback loop involves 2 transcription factors, Clock and Bmal1, which dimerize and bind to E-boxes in the promoters of a large number of target genes. These include Period genes (Per1, Per2, and Per3), Cryptochrome genes (Cry1 and Cry2) and nuclear receptors (Rev-Erba and Rora). Over the course of the day, Per and Cry proteins accumulate and multimerize in the cytoplasm. They translocate to the nucleus in a phosphorylation-dependent manner where they repress the Clock-Bmal1 complex, thus forming the major negative circadian feedback loop. For a new cycle to begin, the inhibitory proteins must be removed. Per and Cry are phosphorylated and degraded, releasing the repression of the Clock-Bmal1 transcriptional activity. Rev-Erba and Rora regulate the transcription of Bmal1 in a separate feedback loop through ROR regulatory elements.
Circadian proteins were traditionally considered as exclusive components of the circadian clock system, ensuring synchronization of numerous processes within an organism, as well as the organism and the environment. However, over the past decade, a growing body of evidence led scientists to change this view. In fact, in mammals, almost all major physiological processes, including sleep-wake cycles, glucose and lipid metabolism, hormone secretion, blood pressure, DNA damage response, immunity and cell-cycle, are influenced by circadian rhythms. 7, 8 Furthermore, perturbations of these rhythms, both in humans (as occurs in night-shift workers) and animal experimental models has been associated with a large array of pathogenic conditions and disorders, such as depression, diabetes, obesity, sleep disorders, and malignant transformation.
Circadian cycles are linked to basic cellular functions, as well as to tissue-specific processes through the control of gene expression and protein interactions. Comprehensive expression profiling studies demonstrated that in any given tissue, up to 10% of transcripts are under circadian control. 9, 10 The Clock-Bmal1 complex directly controls the expression of some of these genes, whereas others are indirectly regulated via circadian expression of relevant transcription factors. Significantly, among the hundreds of proteins exhibiting circadian expression patterns, several are key regulators of cell cycle and apoptosis. For example, c-Myc, a cell cycle transcription factor, and Wee1, a cell cycle checkpoint kinase, contain E-boxes in their promoters and are direct transcriptional targets of Clock-Bmal1 complexes. The levels of the apoptotic proteins such as BCL2 and BAX rhythmically oscillate in murine bone marrow. 11 Studies in mice with mutations in core clock genes clearly demonstrate the critical role for proper circadian regulation to cell cycle progression in peripheral tissues. After partial hepatectomy, livers from cry deficient mice regenerate slower than those from normal mice. In this model, the circadian clock was shown to control the G2/M transition by regulating the expression of Wee1, which negatively regulates the cdc2-cyclin B1 complex, the major cyclin complex governing G2/M. 12 Per2 mutant mice are arrhythmic in constant darkness. Remarkably, Fu et al 13 demonstrated that Per2 mutant mice also exhibit increased susceptibility to both spontaneous and radiation-induced tumor development. Deregulation of c-Myc was proposed as one mechanism by which disruption of the circadian clock could promote tumor formation in Per2 mutant mice. The mutant mice also show aberrant temporal expression of other cell cycle genes such as p53, cyclin A, and mdm2, leading to deregulated cell division and reduced levels of apoptosis. In liver and muscle tissue of clock mutant mice, several cell-cycle inhibitory genes are upregulated, for example, p21(WAF1), p27(Kip1), chk1, chk2, and atr1, whereas proproliferative genes such as jak2, ERa, akt1, cdk2, cyclins D3, and E1, and the TGFb and EGF receptors are downregulated. 14 Fibroblasts derived from clock mutant embryos exhibit reduced DNA synthesis and cell proliferation compared with normal fibroblasts.
A Link Between C/EBPs and the Circadian Clock
Given the proposed links between the circadian clock and cell-cycle regulation, as well as tumor suppression, we hypothesized that the C/EBP-clock axis might play a role in leukemic transformation. We initially set out to verify that Per2 expression is controlled by C/EBP in hematopoietic cells. Analysis of the Per2 promoter region revealed that it contains several potential C/EBP binding sites. Reporter assays showed that C/EBPa and C/EBPe regulate Per2 promoter activity. Electrophoretic mobility shift assay (EMSA) experiments further demonstrated that the transcriptional activation of Per2 is due to direct binding of C/EBPa to the Per2 promoter. Immunoprecipitation (ChIP) experiments using murine bone marrow cells demonstrated that C/EBPa and C/EBPe are specifically associated with the Per2 promoter in vivo. In addition, in human hematopoietic cancer cell lines, stably transfected with inducible CEBPA and CEBPE genes, induction of C/EBPa and C/EBPe led to increase expression of Per2. We also explored the consequences of Per2 overexpression on hematopoietic cell proliferation. Forced expression of Per2 in CML (K562) and myelomonocytic (U937) cancer cell lines led to a dramatic growth inhibition. To analyze additionally the role of Per2 in cell proliferation, we established a Per2-inducible K562 cell line system. Induction of Per2 led to very substantial growth reduction in this cell system. Cellcycle analysis demonstrated significantly increased number of cells in the G2/M phase and decreased number of cells in the S phase of the cell cycle upon indication of Per2. The growth arrest was accompanied by an increase in apoptosis. Additionally, Per2 expressing cells showed reduced anchorage-independent cell growth compared with control K562 cells. The finding that Per2 overexpression results in a significant G2/M arrest is in agreement with other studies showing that the G2/M checkpoint is under circadian control. 13 Nonetheless, genetic and molecular data point to circadian regulation of multiple stages of the cell cycle pathway. In myeloid cells, downregulation of c-Myc is critical for terminal differentiation and growth arrest associated with C/EBPa expression. The molecular pathways underlying Per2 effects in myeloid cells and what role c-Myc, as well as other cell cycle-related genes, plays in mediating these effects remain the subject of further studies.
Our in vitro studies suggested that Per2 has strong antiproliferative effects in hematopoietic cancer cells, and raised the possibility that this gene might be deregulated in hematopoietic malignancies. To address this question, we used real-time reverse transcription-polymerase chain reaction (RT-PCR) to analyze Per2 expression in hematopoietic cancer cell lines, as well as primary patient samples and normal healthy controls. In specific types of human lymphoma cell lines, Per2 levels were extremely low in comparison with its levels in normal human lymph nodes and normal tonsils. Likewise, in samples from patients with AML and specific types of lymphomas, Per2 mRNA expression levels were significantly lower in comparison with levels in normal bone marrow cells and normal tonsils 6 (Koeffler and Thoennissen, unpublished results). Downregulation of Per2 and Per3 associated with increased promoter methylation was also reported in CML patients. 15 Furthermore, combined Per2 and Cry1 expression was suggested as prognostic marker in CML. 16 The complex tissue-specific and temporal expression of thousands of genes in the central clock and the peripheral tissues, suggests that in addition to core clock proteins, other factors may aid in mediating circadian regulation of gene expression. A recent comprehensive meta-analysis of microarray data sets identified C/EBPs, along with a number of other transcription factors, as promising candidates for such circadian transcriptional regulators. 17 Furthermore, a number of studies reported that C/EBPs themselves are rhythmically expressed (possibly by Bamll/ Clock) in various tissues such as heart and liver. 18 These results suggest that C/EBPs may form an additional transcriptional feedback loop contributing to the regulation of core clock genes, as well as to circ adian output pathways (Figure 1 ).
Figure 1. Links between C/EBPs and the circadian clock
The transcriptional activators Clock and Bmal1 drive the expression of core clock genes, as well as the expression of a large number of clockcontrolled genes (such as c-Myc and wee1), thus regulating rhythmic physiological processes throughout the body. C/EBPs integrate into the circadian network by regulating the expression of core clock genes directly. Additionally, C/EBPs themselves are rhythmically expressed in some tissues and may also influence the activity of the core clock transcriptional mechanism (dashed lines). C/EBPs may therefore form an additional feedback loop contributing to the fine tuning of circadian regulation.
In summary, these data support a model in which Per2 is an important downstream C/EBP target gene that may be involved in C/EBPa-induced growth arrest and block of differentiation, the hallmarks of myeloid transformation. Furthermore, the newly identified links between C/EBPs and the core circadian apparatus suggest that C/EBP may be part of the intricate network orchestrating circadian regulation of diverse cellular processes such as metabolic pathways and cell cycle progression. Future studies on the relationship between C/EBPs and circadian genes will advance our understanding of the molecular basis of their physiological role and may lead to the development of new therapeutics.
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